Loading clinical trials...
Loading clinical trials...
The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Bispebjerg Hospital
Copenhagen, Denmark
Rigshospitalet
Copenhagen, Denmark
Herlev and Gentofte Hospital
Herlev, Denmark
Steno Diabetes Center Copenhagen
Herlev, Denmark
Nordsjællands Hospital
Hillerød, Denmark
Holbæk Sygehus
Holbæk, Denmark
Hvidovre Hospital
Hvidovre, Denmark
Sjællands Universitetshospital
Køge, Denmark
Nykøbing F. Sygehus
Nykøbing Falster, Denmark
Sjællands Universitetshospital
Roskilde, Denmark
Start Date
October 10, 2024
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2028
Last Updated
November 5, 2024
17,200
ESTIMATED participants
Empagliflozin 10 MG
DRUG
Dapagliflozin 10 MG
DRUG
Lead Sponsor
Herlev and Gentofte Hospital
NCT07191730
NCT07484009
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions